Drugs group Innovata today agreed a deal to allow US rival Baxter International to market its treatment for internal scarring suffered during surgery. Innovata has handed control of its Adept treatment to Baxter in markets around the world including Japan, enabling it to focus more directly on the United States. Adept was launched in 2000 and was previously licensed to UK firm Shire Pharmaceuticals in Europe.

Irish Examiner (http://www.irishexaminer.com/breaking/story.asp?j=3565410&p=35654z5&n=3565502)